MAPT and Alzheimer disease: In human subjects with AD at early clinical stages, cerebrospinal fluid levels of MIF were increased in comparison with age-matched controls, and correlated with biomarkers of tau hyper-phosphorylation and neuronal injury suggesting that MIF can play a role as biomarker for early-stage AD.